On Wednesday the U.S. Patent Trial and Appeal Board invalidated the last remaining patent on abiraterone acetate (Zytiga), making it possible that generic forms of abiraterone acetate would be available in 2018 (at least in the US). … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, cost, generic, patent, Zytiga | Leave a comment »
On Monday December 11 (next week) phase I of the availability of generic Viagra will kick in (here in the US), and those of us who need / want this product to help cope with ED should see a roughly 50 percent drop in the price … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: ED, generic, sildenafil, Viagra | 3 Comments »
In what may be an important piece of information for many men with prostate cancer, the U.S. Food and Drug Administration yesterday approved the first generic form of the erectile dysfunction drug sildenafil or Viagra. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: generic, sildenafil, Viagra | 3 Comments »
According to a story on the FiercePharma web site, the patent for sildenafil (Viagra) will expire today in Europe. This ought to lead to a significant drop in the price for a very popular drug as generic equivalents rapidly come available. Here in the USA, however, Pfizer has managed to extend the patent for Viagra to 2020 (through litigation).
Filed under: Living with Prostate Cancer | Tagged: generic, patent, sildenafil, Viagra | 2 Comments »
According to a report from the Associated Press, generic bicalutamide (the generic form of Casodex) is now available in the USA after approval by the US Food and Drug Administration. This offers a significant potential cost saving for many prostate cancer patients that they may want to take advantage of.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, Casodex, generic | Comments Off on Generic bicalutamide now available in the USA
THE "NEW" PROSTATE CANCER INFOLINK 